Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

A ceremony marking the start of construction on AstraZeneca's new small molecule drug factory is held in Wuxi, East China's Jiangsu province, on May 8. [Photo provided to chinadaily.com.cn] ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its ...

AstraZeneca presented data from the phase 3 BATURA study which showed that use of Airsupra in those with mild asthma reduced ...

rNIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK sUniversity Hospitals Sussex NHS Foundation Trust, ...

On May 8, 2025, the Court of Appeals for the Third Circuit affirmed the district court’s dismissal of AstraZeneca’s challenges to the Inflation Reduction Act’s Drug Price Negotiation Program ...

AstraZeneca will present over 75 abstracts, including studies on albuterol/budesonide therapy for asthma and triple inhaled therapy for COPD. Biodesix will present data on Nodify Lung tests ...

AstraZeneca will present the latest clinical and real-world ... chronic bronchitis and smoking status. • Tozorakimab: Demonstrating potential benefits of tozorakimab to reduce excess inflammation in ...

Controlling the entire cell therapy production process—from material receipt to product release—is “essential,” according to AstraZeneca, which says its new $300 million manufacturing ...

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best pharma stocks to invest in now amid the domestic manufacturing boom. Domestic ...

WILMINGTON, Del., May 13, 2025--(BUSINESS WIRE)--AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at ...